Skip to main content
Top
Published in: Supportive Care in Cancer 11/2021

01-11-2021 | Mood Disorders | Original Article

Psychotropic medications in oncology

Authors: Erin K. Biringen, Emily Cox-Martin, Sierra Niemiec, Cheyret Wood, W. Thomas Purcell, Elissa Kolva

Published in: Supportive Care in Cancer | Issue 11/2021

Login to get access

Abstract

Context

Psychological distress is common in patients with cancer, and oncology providers are often tasked with utilizing psychotropic medications to treat such symptoms.

Objective

This study aims to characterize how oncology providers prescribe psychotropic medications and to assess their comfort level with prescribing these medications.

Methods

A cross-sectional survey was sent to oncology medical doctors, nurse practitioners, and physician assistants who prescribe psychotropic medications to patients with cancer at a large academic medical center in the Mountain West. The survey included questions regarding provider subspecialty, degree, comfort with prescribing psychotropic medications, and factors that informed their prescribing.

Results

Oncology providers (n = 65) reported equal proportions of comfort and discomfort with prescribing psychotropic medications. The medication class with the most prescribers was benzodiazepines, with 89.2% (n = 58) of the respondents prescribing those medications. The least prescribed category was mood stabilizers, with 4.6% (n = 3) prescribing this category. Prescribers identified that barriers to their comfort included difficulty connecting patients to follow-up care with mental health professionals and inadequate mental health education for providers. Providers responded that continuing mental health education and increasing patient access to mental health resources would increase their prescribing comfort.

Conclusion

Providers reported equal parts comfort and discomfort with prescribing psychotropic medications; avenues to increase comfort should involve focused mental health education during formal training and continued education throughout their oncology careers. A clinical pathway for prescribing psychotropic medications with resources to connect patients to long-term mental health care may also increase prescribing comfort.
Literature
1.
go back to reference Pitman A, Suleman S, Hyde N, Hodgkiss A (2018) Depression and anxiety in patients with cancer. BMJ 361:k1415CrossRef Pitman A, Suleman S, Hyde N, Hodgkiss A (2018) Depression and anxiety in patients with cancer. BMJ 361:k1415CrossRef
2.
go back to reference McFarland DC, Holland JC (2016) The management of psychological issues in oncology. Clin Adv Hematol Oncol 14:999–1009PubMed McFarland DC, Holland JC (2016) The management of psychological issues in oncology. Clin Adv Hematol Oncol 14:999–1009PubMed
3.
go back to reference Chou C, Hohmann NS, Hastings TJ et al (2020) How comfortable are primary care physicians and oncologists prescribing medications for comorbidities in patients with cancer? Res Social Adm Pharm 16:1087–1094CrossRef Chou C, Hohmann NS, Hastings TJ et al (2020) How comfortable are primary care physicians and oncologists prescribing medications for comorbidities in patients with cancer? Res Social Adm Pharm 16:1087–1094CrossRef
4.
go back to reference Sanjida S, Janda M, Kissane D et al (2016) A systematic review and meta-analysis of prescribing practices of antidepressants in cancer patients. Psychooncology 25:1002–1016CrossRef Sanjida S, Janda M, Kissane D et al (2016) A systematic review and meta-analysis of prescribing practices of antidepressants in cancer patients. Psychooncology 25:1002–1016CrossRef
5.
go back to reference Granek L, Nakash O, Ben-David M, Shapira S, Ariad S (2018) Oncologists’ treatment responses to mental health distress in their cancer patients. Qual Health Res 28:1735–1745CrossRef Granek L, Nakash O, Ben-David M, Shapira S, Ariad S (2018) Oncologists’ treatment responses to mental health distress in their cancer patients. Qual Health Res 28:1735–1745CrossRef
6.
go back to reference Thekdi S, Trinidad A, Roth A (2015) Psychopharmacology in cancer. Curr Psychiatry Rep 17:529CrossRef Thekdi S, Trinidad A, Roth A (2015) Psychopharmacology in cancer. Curr Psychiatry Rep 17:529CrossRef
7.
go back to reference Wang C, Huang LC, Yang C et al (2017) Short- and long-term use of medication for psychological distress after the diagnosis of cancer. Support Care Cancer 25:757–768CrossRef Wang C, Huang LC, Yang C et al (2017) Short- and long-term use of medication for psychological distress after the diagnosis of cancer. Support Care Cancer 25:757–768CrossRef
8.
go back to reference Farriols C, Ferrández O, Planas J et al (2012) Changes in the prescription of psychotropic drugs in the palliative care of advanced cancer patients over a seven-year period. J Pain Symptom Manag 42:945–952CrossRef Farriols C, Ferrández O, Planas J et al (2012) Changes in the prescription of psychotropic drugs in the palliative care of advanced cancer patients over a seven-year period. J Pain Symptom Manag 42:945–952CrossRef
9.
go back to reference Holch P, Absolom K, Pini S et al (2011) Oncology professionals’ views on the use of antidepressants in cancer patients: a qualitative interview study. BMJ Support Palliat Care 3:301–305CrossRef Holch P, Absolom K, Pini S et al (2011) Oncology professionals’ views on the use of antidepressants in cancer patients: a qualitative interview study. BMJ Support Palliat Care 3:301–305CrossRef
10.
go back to reference Sansone R, McDonald S, Prutzman C, Henkaline TC (2006) The comfort level of internists with the prescription of psychotropic medication. Int J Psychiatry Med 36:85–92CrossRef Sansone R, McDonald S, Prutzman C, Henkaline TC (2006) The comfort level of internists with the prescription of psychotropic medication. Int J Psychiatry Med 36:85–92CrossRef
11.
go back to reference Harris PA, Taylor R, Minor BL et al (2019) The REDCap consortium: building an international community of software platform partners. J Biomed Inform 95:103208CrossRef Harris PA, Taylor R, Minor BL et al (2019) The REDCap consortium: building an international community of software platform partners. J Biomed Inform 95:103208CrossRef
12.
go back to reference Harris PA, Taylor R, Thielke R et al (2009) Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2:377–381CrossRef Harris PA, Taylor R, Thielke R et al (2009) Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2:377–381CrossRef
14.
go back to reference Ge Y, Sealfon SC, Speed SP (2008) Some step-down procedures controlling the false discover rate under dependence. Stat Sin 18:881–904PubMedPubMedCentral Ge Y, Sealfon SC, Speed SP (2008) Some step-down procedures controlling the false discover rate under dependence. Stat Sin 18:881–904PubMedPubMedCentral
15.
go back to reference Mircioiu C, Atkinson J (2017) A comparison or parametric and non-parametric methods applied to a likert scale. Pharmacy (Basel) 5:26CrossRef Mircioiu C, Atkinson J (2017) A comparison or parametric and non-parametric methods applied to a likert scale. Pharmacy (Basel) 5:26CrossRef
16.
go back to reference Fox J, Weisberg S (2019) An R comparison to applied regression, 3rd edn. Sage Publications, Thousand Oaks Fox J, Weisberg S (2019) An R comparison to applied regression, 3rd edn. Sage Publications, Thousand Oaks
Metadata
Title
Psychotropic medications in oncology
Authors
Erin K. Biringen
Emily Cox-Martin
Sierra Niemiec
Cheyret Wood
W. Thomas Purcell
Elissa Kolva
Publication date
01-11-2021
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 11/2021
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-021-06283-w

Other articles of this Issue 11/2021

Supportive Care in Cancer 11/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine